Table 6 Drug treatment and outcomes of the disease, in pregnant and non-pregnant women with confirmed SARS-CoV-2 infection
From: Covid-19 infection in pregnant women in Dubai: a case-control study
Pregnant women (n = 79) | Non-pregnant women (n = 85) | P-value | |
|---|---|---|---|
No. (%) | No. (%) | ||
Hydroxychloroquine | 38 (48) | 44 (52) | 0.377 |
Favipiravir | 0 | 22 (26) | < 0.001 |
Lopinavir-Ritonavir | 15 (19) | 15 (18) | 0.492 |
Azithromycin | 11 (14) | 8 (10) | 0.255 |
Chloroquine | 3 (4) | 16 (19) | 0.002 |
LMWH | 64 (81) | 30 (35) | < 0.001 |
Methylprednisolone | 12 (15) | 7 (8) | 0.126 |
Interferon | 3 (4) | 0 | 0.110 |
Acetylcysteine | 5 (6) | 4 (5) | 0.454 |
Antibiotics | 30 (30) | 11 (13) | < 0.001 |
Vitamin C/Vitamin D | 68 (86) | 79 (93) | 0.118 |
O2 support/ventilated | 10 (13) | 4 (5) | 0.061 |
Complication | 9 (11) | 2 (2) | 0.124 |
Recovery time | |||
Mean (SD) | 16 (11) | 15 (7) | 0.453 |
Death | 1 (1) | 0 | 0.481 |